Recursion Pharmaceuticals, INC Schedule 13G passive stakes

State Street Corporation has filed a Schedule 13G, reporting beneficial ownership of 6.6% of Recursion Pharmaceuticals Inc. common stock as of June 30, 2026.

Vanguard Portfolio Management has reported beneficial ownership of 5.97% of Recursion Pharmaceuticals Inc. common stock as of June 30, 2026.

Vanguard Capital Management has reported beneficial ownership of 26,744,129 shares, representing 5.09% of Recursion Pharmaceuticals Inc.'s common stock.

State Street Corporation has reported a beneficial ownership of 5.5% in Recursion Pharmaceuticals Inc. as of March 31, 2026.

The Vanguard Group filed an amended Schedule 13G, reporting 0% beneficial ownership in Recursion Pharmaceuticals Inc. following an internal realignment.

Baillie Gifford & Co. reported a 4.6% beneficial ownership in Recursion Pharmaceuticals Class A Common Stock as of December 31, 2025.

ARK Investment Management and Catherine D. Wood affirm their significant 7.25% beneficial ownership in Recursion Pharmaceuticals, Inc. via a Schedule 13G filing.

RA Capital Management, along with Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., has filed an amendment to their Schedule 13G, disclosing a reduced beneficial ownership of 2.0% in Recursion Pharmaceuticals, Inc. as of December 31, 2024.

ARK Investment Management LLC has filed an amended Schedule 13G, revealing a beneficial ownership of 8.47% of Recursion Pharmaceuticals, Inc.'s Class A Common Stock as of December 31, 2024.

Baillie Gifford & Co. has filed an Amendment No. 5 to Schedule 13G, disclosing a 6.5% beneficial ownership stake in Recursion Pharmaceuticals, Inc. as of December 31, 2024.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 6.1% beneficial ownership stake in Recursion Pharmaceuticals, Inc. as of December 31, 2024.